Op-eds: Canadian and American regulators, law enforcement and patient advocates oppose drug importation

Since 2000, every head of the United States Food and Drug Administration (FDA) and United States Department of Health and Human Services (HHS) has opposed drug importation because the benefits that might be gained are far outweighed by the many dangers. Law enforcement, patient advocates, pharmacy groups, and regulators agree.

Former Assemblyman Reminds Everyone That Drug Importation Is Bad For Alaska

Oct 2, 2017

Paul Honeman is a former Anchorage Assemblyman representing East Anchorage. He also is a retired Anchorage Police Department Lieutenant. In this September 28, 2017 editorial in The Bristol Bay Times, he highlights the dangers posed by drug importation and reminds everyone why it is currently banned…

Dr. Shepherd at the Interchange

Separating fact from fiction about drug importation at CNN’s recent Healthcare Town Hall

Sep 29, 2017

CNN’s September 25, 2017 Healthcare Town Hall was an opportunity for prominent senators to share important ideas about ways to improve Americans’ lives, but it also included some erroneous statements about drug importation. PSM’s Board President, Dr. Marv Shepherd, sent this letter on September 29 to clarify those issues.

NV Sheriffs’ and Chiefs’ Association Tells Sen. Heller They Oppose Allowing Drug Importation

Sep 23, 2017

The Nevada Sheriffs’ and Chiefs’ Association sent a letter to Senator Heller explaining their reasons for opposing S. 469, the bill that would allow drug importation…

Texas Policy Analyst Questions Economic Impact and Safety of Drug Importation

Sep 22, 2017

Russell Withers, general counsel at the Texas Conservative Coalition Research Institute in Austin, believes that drug importation is “neither affordable nor safe.” In a September 20, 2017 editorial in the Austin-American Statesman , he argues that “it would hurt U.S. and Texas businesses, workers and patients’ and urges Texan congress members to oppose it.

Former FBI agent warns that drug importation risks “counterfeiting, fraud and powerful narcotics in the wrong hands”

Sep 22, 2017

Former FBI agent Eric O’Neill warned about the dangers of drug importation in Inside Sources on September 20, 2017. “The lull of normalcy,” he writes, “masks very real threats to a relatively well-functioning system, including counterfeiting, fraud and powerful narcotics in the wrong hands…while costs are important, we shouldn’t circumvent the safeguards that keep our medicines safe and reliable.”

US Will Be Exposed to Counterfeits From Weak European Drug Security Warns Expert

Aug 28, 2017

In early July, European authorities reported that counterfeit versions of Omnitrope, a drug containing human growth hormone, were found in France, Denmark, and Mexico. The counterfeit Omnitrope was designed to look like it was made by a large drug manufacturer, but it contained no active ingredient. Shortly thereafter, German authorities announced that a fake version of a schizophrenia drug, Xeplion, was discovered in Germany. The Xeplion was also a knock-off, mimicking packaging used in Bulgaria and Romania.

These incidents are the latest in a stream of reports about counterfeit drugs throughout Europe. The problem lies in lax security of the supply chain — distributors, middlemen and wholesalers between the drug maker and the consumer. Despite ongoing problems with the EU drug supply chain, Congress is currently considering a bill that would open the U.S. to imports from the EU and elsewhere. We can’t have a serious debate about drug importation without understanding what is going on in Europe.

DEA Agent Warns That a Single Fake Pill Containing Fentanyl Can Be a Death Sentence

Aug 25, 2017

Daniel R. Salter is a 30-year veteran of the U.S. Drug Enforcement Agency who has witnessed firsthand the devastation that fentanyl is causing to communities and the strain it is putting on law enforcement resources in Georgia…

JAMA editorial supports declaring the opioid epidemic a national emergency

Aug 25, 2017

An August 23, 2017 editorial in the Journal of American of the American Medical Association (JAMA) supports President Trump’s stated intention to declare the nation’s opioid epidemic a national emergency.

Health Policy Expert: “Why Cheaper Drugs Can Kill”

Aug 24, 2017

Health policy expert Kenneth Thorpe weighs in on the dangers of drug importation in this August 23, 2017 editorial in U.S. News & World Report:

“…these savings could come at the cost of Americans’ lives. Legalizing drug importation would make it far easier for harmful counterfeit and contaminated medicines to enter the U.S. drug supply. At a time when illegal, counterfeit drugs already cause hundreds of American deaths every year, importation represents a reckless way to cut health care costs.”

Bioworld: Importation a cliché, not a CAPA

Aug 21, 2017

Mari Serebrov, the regulatory editor for biotechnology news site BioWorld, offered this opinion about drug importation on August 4, 2017.  

“On the surface, importing drugs from Canada seems like a no-brainer,” she writes, “especially when the Canadian version is virtually the same drug as the one approved by the FDA for the U.S. market – except a whole lot cheaper. But there’s the rub. How can Congress ensure that drugs imported from Canada are all that they claim to be?

While more than 40 countries have or are implementing security measures to protect their drug supply chain, Canada’s not one of them, Brian Daleiden, vice president of industry marketing at Tracelink Inc., told BioWorld. That puts importation – from Canada, at least – on a collision course with the U.S. Drug Supply Chain Security Act (DSCSA), which Congress passed in 2013 as part of the Drug Quality and Security Act.”